Short regimen of praziquantel in the treatment of single brain enhancing lesions

Pretell, E. Javier; Garcı́a, Héctor H.; Custodio, Nilton; Padilla, Carmen; Alvarado, Manuel; Gilman, Robert H.; Martı́nez, Manuel

doi:10.1016/s0303-8467(00)00110-4

Cited by 39 publications

(24 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[27][28][29][30] Eventually, 10 RCTs, involving 765 subjects with SCG, were included in the meta-analysis of anthelminthic treatment. [31][32][33][34][35][36][37][38][39][40] In one of these, some subjects had 2 rather than a single enhancing lesion. 36 We chose to include this trial because the proportion of subjects with 2 lesions was small (18%).…”

Section: 15mentioning

confidence: 99%

See 1 more Smart Citation

Drug therapy for solitary cysticercus granuloma

et al. 2013

View full text Add to dashboard Cite

Objective: The effectiveness of anthelminthic and corticosteroid drug therapy in parenchymal neurocysticercosis is well established. The treatment of parenchymal solitary cysticercus granuloma (SCG), however, remains controversial. We attempted to obtain a consistent estimate of the efficacy of anthelminthic and corticosteroid drug treatment in SCG.Methods: Randomized-controlled trials (RCTs) comparing rates of seizure freedom, granuloma resolution, and residual calcification in individuals with SCG treated with anthelminthic or corticosteroid drugs with those treated with antiepileptic drugs (AEDs) alone were systematically reviewed and quantified using fixed-or random-effects meta-analysis.Results: Fifteen RCTs were identified for inclusion. Ten RCTs assigned 765 people with SCG to AED treatment with or without anthelminthic drug (albendazole) treatment. A further 5 RCTs assigned 457 people with SCG to AED treatment with or without corticosteroid drugs. Anthelminthic treatment was associated with significantly increased rates of seizure freedom (nonevent odds ratio: 2.45; 95% confidence interval: 1.49-4.03; p 5 0.0004) and significantly higher rates of granuloma resolution (odds ratio: 2.09; 95% confidence interval: 1.41-3.00; p 5 0.0003), but did not alter the risk of residual calcification. Corticosteroid treatment was not significantly associated with any outcome. Conclusions:

show abstract

Section: 15mentioning

confidence: 99%

“…31,32,34,[36][37][38][39][40] Five RCTs reported resolution at 6 months follow-up time using CT 31,33,35,39,40 or MRI acquisition. 34 All CT studies but one 35 used contrast-enhanced acquisition.…”

Section: E1-e5mentioning

confidence: 99%

Drug therapy for solitary cysticercus granuloma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Recently, a single-day scheme was proposed (25 mg/kg at 2 h intervals) leading to a 90% reduction of the direct costs in relation to the traditional scheme and preliminary results were encouraging [8,15,[26][27][28]. The decrease in the number of cysts visualized in neuroimaging studies was similar to that observed in patients receiving longer courses of PZQ at conventional doses [8,15,27,29,30]. However, the parasiticidal results obtained by Pretell and colleagues were unsatisfactory in patients with multiple lesions, in whom all cysts persisted unchanged [31].…”

Section: Anticysticercal Drugsmentioning

confidence: 99%

Therapy for neurocysticercosis

Takayanagui

2004

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

“…The decrease in the number of cysts visualized on neuroimaging studies after a 1-day therapy is similar to that observed in patients receiving longer courses of the drug at conventional doses. 10,17,39,46 Albendazole is another strong cysticidal drug, initially tested at doses of 15 mg/kg/day for a 1-month period. 28 It was later found, however, that at similar doses the length of therapy could be shortened to 1 week without lessening the drug efficacy.…”

Section: Cysticidal Drugsmentioning

confidence: 99%

Review of neurocysticercosis

Sotelo¹,

Brutto²

2002

FOC

View full text Add to dashboard Cite

In the neurosurgical services in many developing countries, treatment of neurocysticercosis (NCC) accounts for greater than 10% of brain surgical procedures and approximately 15% of neurological consultations. In these areas brain cysticercosis is the leading cause of hydrocephalus in adults and the first cause of late-onset epilepsy. During the last two decades, successful medical treatment has been established. Additionally, neuroimaging and immunological studies have clearly defined the topography, pathophysiological mechanisms, and biological status of these lesions. Thus, selection of cases for medical or surgical treatment has improved; in a significant number of cases, both interventions are required. New therapies with either albendazole or praziquantel have respectively reduced to 8 days and to 1 day the course of anticysticidal therapy, which now is fast, effective, inexpensive, atoxic, and convenient, particularly in endemic areas where most patients belong to the lower socioeconomic groups. Additionally, the rational use of steroid agents facilitates the treatment of inflammation, a conspicuous accompaniment in cases of NCC. A major effort, however, is still required to eradicate this disease.

show abstract

Short regimen of praziquantel in the treatment of single brain enhancing lesions

Cited by 39 publications

References 13 publications

Drug therapy for solitary cysticercus granuloma

Drug therapy for solitary cysticercus granuloma

Therapy for neurocysticercosis

Review of neurocysticercosis

Contact Info

Product

Resources

About